Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atropine + pralidoxime + magnesium sulfate
- Development stage
- Unknown
- Lead developer
- Muhammad Aamir Latif
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Atropine + pralidoxime + magnesium sulfate is an investigational combination regimen being studied for the treatment of acute organophosphate (OP) poisoning. This therapeutic approach combines three agents with distinct mechanisms to address the complex pathology of OP toxicity: atropine serves as a muscarinic receptor antagonist to block the effects of excess acetylcholine; pralidoxime acts as an acetylcholinesterase reactivator to restore the function of the inhibited enzyme; and magnesium sulfate is used as an adjunctive agent to stabilize neuromuscular junctions and provide calcium channel blockade. The regimen is primarily being evaluated in clinical trials to determine if the addition of magnesium sulfate to standard atropine and pralidoxime therapy can reduce mortality and the total requirement for atropine in poisoned patients.
- Other names
- atropine plus pralidoxime plus magnesium sulfateatropine and pralidoxime with adjunctive MgSO4
02
Targets
AcetylcholinesteraseCaV (Voltage-gated calcium channel protein complex)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on atropine + pralidoxime + magnesium sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atropine + pralidoxime + magnesium sulfate.